Apollo HealthCo targets Q1FY27 cash breakeven as Keimed merger reshapes pharmacy retail arm
Apollo Hospitals' omnichannel pharmacy and digital health unit eyes cash breakeven by Q1FY27 on FY26 revenue of ₹25,229 crore (+16% YoY). Restructuring will demerge it into Apollo Healthtech and absorb Keimed's pharma distribution, with a shareholder vote slated for June 2026.
What happened
Apollo HealthCo, Apollo Hospitals' omnichannel pharmacy and digital health arm, targets cash breakeven in Q1FY27 amid restructuring that will demerge it into
Key facts
- Q1FY27 breakeven
- FY26 revenue ₹25,229 crore
- 16% YoY growth
- capex ₹1,500 crore
- 8,131 beds
- 68% occupancy
- 1,500 beds addition
- 10,600 beds target
Why this matters
Apollo's consolidation of Keimed's pharma distribution into a demerged Healthtech entity signals a vertically integrated omnichannel pharmacy play that reshapes the competitive set for PharmEasy, Tata 1mg, and Netmeds.